DMDavid H. Murray

David H. Murray

*This is an algorithmically generated author record based on publicly available information.

David H. Murray has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection

    by Erin L. Symonds, Susanne K. Pedersen, David H. Murray, Maher Jedi, Susan E. Byrne, Philippa Rabbitt, Rohan T. Baker, Dawn Bastin, Graeme P. Young

    Cell-free circulating tumour-derived DNA (ctDNA) can be detected by testing for methylated BCAT1 and IKZF1 DNA, which has proven sensitivity for colorectal cancer (CRC). A prospective correlative biomarker study between presence of methylated BCAT1 and IKZF1 in tissue and blood was conducted in cases with CRC to explore how detection of such ctDNA biomarkers relates to cancer characteristics, methylation in tissue and surgical resection of the primary cancer. Enrolled patients with invasive CRC had blood collected at diagnosis, prior to any treatment or surgery (peri-diagnostic sample). A subgroup of patients also had cancer and adjacent non-neoplastic tissue collected at surgical resection, as well as a second blood sample collected within 12 months of surgery (post-surgery sample). DNA was extracted from all samples and assayed for methylated BCAT1 and IKZF1 to determine the degree of methylation in tissue and the presence of ctDNA in blood. Of 187 cases providing peri-diagnostic blood samples, tissue was available in 91, and 93 provided at least one post-surgery blood sample for marker analysis. Significant methylation of either BCAT1 or IKZF1 was seen in 86/91 (94.5%) cancer tissues, with levels independent of stage and higher than that observed in adjacent non-neoplastic specimens (P < 0.001). ctDNA methylated in BCAT1 or IKZF1 was detected in 116 (62.0%) cases at diagnosis and was significantly more likely to be detected with later stage (P < 0.001) and distal tumour location (P = 0.004). Of the 91 patients who provided pre-and post-surgery blood samples, 47 patients were ctDNA-positive at diagnosis and 35 (74.5%) became negative after tumour resection. This study has shown that BCAT1 and IKZF1 methylation are common events in CRC with almost all cancer tissues showing significant levels of methylation in the two genes. The presence of ctDNA in blood is stage-related and show rapid reversion to negative following surgical resection. Monitoring methylated BCAT1 and IKZF1 levels could therefore inform adequacy of surgical resection. Australian New Zealand Clinical Trial Registry number 12611000318987 . Registered 25 March 2011.


  • Mo1973 - Circulating Tumor DNA to Assess Characteristics of Colorectal Cancer and Completeness of Surgical Resection

    by Erin Symonds, Susanne K. Pedersen, David H. Murray, Maher Jedi, Susan Byrne, Philippa Rabbitt, Rohan Baker, Dawn Bastin, Graeme P. Young

  • Open Access

    Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia

    by Susanne K. Pedersen, Erin L. Symonds, Rohan T. Baker, David H. Murray, Aidan McEvoy, Sascha C. Van Doorn, Marco W. Mundt, Stephen R. Cole, Geetha Gopalsamy, Dileep Mangira, et al.

    Specific genes, such as BCAT1 and IKZF1, are methylated with high frequency in colorectal cancer (CRC) tissue compared to normal colon tissue specimens. Such DNA may leak into blood and be present as cell-free circulating DNA. We have evaluated the accuracy of a novel blood test for these two markers across the spectrum of benign and neoplastic conditions encountered in the colon and rectum. Circulating DNA was extracted from plasma obtained from volunteers scheduled for colonoscopy for any reason, or for colonic surgery, at Australian and Dutch hospitals. The extracted DNA was bisulphite converted and analysed by methylation specific real-time quantitative PCR (qPCR). A specimen was deemed positive if one or more qPCR replicates were positive for either methylated BCAT1 or IKZF1 DNA. Sensitivity and specificity for CRC were estimated as the primary outcome measures. Plasma samples were collected from 2105 enrolled volunteers (mean age 62 years, 54 % male), including 26 additional samples taken after surgical removal of cancers. The two-marker blood test was run successfully on 2127 samples. The test identified 85 of 129 CRC cases (sensitivity of 66 %, 95 % CI: 57–74). For CRC stages I-IV, respective positivity rates were 38 % (95 % CI: 21–58), 69 % (95 % CI: 53–82), 73 % (95 % CI: 56–85) and 94 % (95 % CI: 70–100). A positive trend was observed between positivity rate and degree of invasiveness. The colonic location of cancer did not influence assay positivity rates. Gender, age, smoking and family history were not significant predictors of marker positivity. Twelve methylation-positive cancer cases with paired pre- and post-surgery plasma showed reduction in methylation signal after surgery, with complete disappearance of signal in 10 subjects. Sensitivity for advanced adenoma (n = 338) was 6 % (95 % CI: 4–9). Specificity was 94 % (95 % CI: 92–95) in all 838 non-neoplastic pathology cases and 95 % (95 % CI: 92–97) in those with no colonic pathology detected (n = 450). The sensitivity for cancer of this two-marker blood test justifies prospective evaluation in a true screening population relative to a proven screening test. Given the high rate of marker disappearance after cancer resection, this blood test might also be useful to monitor tumour recurrence. ACTRN12611000318987 .


  • 228 Evaluation of a 2-Gene (IKZF1 and BCAT1) DNA Blood Test for Detection of Colorectal Cancer

    by Graeme P. Young, Susanne K. Pedersen, Evelien Dekker, Stephen R. Cole, Joanne M. Osborne, Erin L. Symonds, Rosalie C. Mallant-Hent, Aidan Mcevoy, Rohan Baker, Snigdha Gaur, et al.


  • 135 Discovery and Validation of a Novel DNA Methylation Biomarker for Colorectal Cancer With Application to Blood Testing

    by Susanne K. Pedersen, Peter L. Molloy, Rohan Baker, Aidan McEvoy, Melissa L. Thomas, David H. Murray, Rob Dunne, Trevor Lockett, Susan M Mitchell, Thu Ho, et al.